JPS57179118A - Antitumor agent - Google Patents

Antitumor agent

Info

Publication number
JPS57179118A
JPS57179118A JP6359481A JP6359481A JPS57179118A JP S57179118 A JPS57179118 A JP S57179118A JP 6359481 A JP6359481 A JP 6359481A JP 6359481 A JP6359481 A JP 6359481A JP S57179118 A JPS57179118 A JP S57179118A
Authority
JP
Japan
Prior art keywords
cysteine
fluorouracil
antitumor
antitumor agent
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP6359481A
Other languages
Japanese (ja)
Other versions
JPS6348245B2 (en
Inventor
Shizumasa Sugiyama
Nobuo Kawabata
Tsukasa Kuwamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ESUESU SEIYAKU KK
SSP Co Ltd
Original Assignee
ESUESU SEIYAKU KK
SSP Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ESUESU SEIYAKU KK, SSP Co Ltd filed Critical ESUESU SEIYAKU KK
Priority to JP6359481A priority Critical patent/JPS57179118A/en
Publication of JPS57179118A publication Critical patent/JPS57179118A/en
Publication of JPS6348245B2 publication Critical patent/JPS6348245B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PURPOSE: To prepare an antitumor agent having high safety, by combining 1-(2- tetrahydrofuryl)-5-fluorouracil with L-cysteine.
CONSTITUTION: The objective antitumor agent can be obtained by combining 1-(2-tetrahydrofuryl)-5-fluorouracil (FT) with L-cysteine at a molar ratio of 1 to ≥0.3. The FT is a derivative of 5-fluorouracil (5-FU) having antitumor activity. The combined use of FT and L-cysteine remarkably raises the concentration of FT and 5-FU in the blood plasma and the liver, and improves the antitumor effect. Dose: preferably 15W500mg/kg/day for FT and ≥3mg/kg/day for L- cysteine. The agent is preferably administered in the form of an oral drug such as tablet, capsule, etc. for FT, and the above oral drug or an injection for L- cysteine.
COPYRIGHT: (C)1982,JPO&Japio
JP6359481A 1981-04-27 1981-04-27 Antitumor agent Granted JPS57179118A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP6359481A JPS57179118A (en) 1981-04-27 1981-04-27 Antitumor agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6359481A JPS57179118A (en) 1981-04-27 1981-04-27 Antitumor agent

Publications (2)

Publication Number Publication Date
JPS57179118A true JPS57179118A (en) 1982-11-04
JPS6348245B2 JPS6348245B2 (en) 1988-09-28

Family

ID=13233743

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6359481A Granted JPS57179118A (en) 1981-04-27 1981-04-27 Antitumor agent

Country Status (1)

Country Link
JP (1) JPS57179118A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes

Also Published As

Publication number Publication date
JPS6348245B2 (en) 1988-09-28

Similar Documents

Publication Publication Date Title
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
JO1502B1 (en) Novel pharmacological compounds
MA21264A1 (en) COMPOSITION FOR ADMINISTERING MEDICAMENT IN THE FORM OF CELLS, POWDER OR LIQUID.
ES482153A1 (en) Phenethanolamines, their formulations, preparation and use.
JPS5781409A (en) External plaster
JPS57179118A (en) Antitumor agent
CA2078869A1 (en) Pharmaceutical compositions containing ipriflavone, process for the preparation thereof and relative therapeutic use
JPS56138110A (en) Suppository containing citric acid or salt thereof
MY101916A (en) Etoposide oral dosage form.
JPS5551019A (en) Drug containing alllee or 133zz7*88dehydroo retine acid and manufacture thereof
JPS5793913A (en) Enhancing agent for spermous vital power
JPS57114512A (en) Antidia beticagent comprising (3-dimethyl-carbamoxy- phenyl)trimethyl ammonium derivative
JPS646214A (en) Remedy for ulcerative colonopathy
JPS57167912A (en) Antitumor agent
JPS56138112A (en) Suppository containing ascorbic acid or sodium ascorbate
JPS56115715A (en) Physiologically active agent containing (3- dimethylcarbam-oxyphenyl) trimethyl ammonium derivative
JPS56164120A (en) Antitumor agent
JPS5569510A (en) Carcinostatic agent
ES2016052A6 (en) Nucleotide derivatives.
GB1327464A (en) Pharmaceutical composition for inhibiting indoleamine-n- methyl transferase
GB1429977A (en) Diuretic composition
JPS5498339A (en) Carcinostatic agent
ES469648A1 (en) Oleandomycin derivatives
JPS5742620A (en) Novel antiulcer agent
GB1279380A (en) Improvements in or relating to hydantoins and compositions thereof